Brain capillary endothelial cells form the blood-brain barrier (BBB), which is covered with
basement membranes and is also surrounded by pericytes and astrocyte end-feet in the …

Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

Alzheimer's disease (AD) and treatment of the brain in aging require the development of
new biologic drugs, such as recombinant proteins or gene therapies. Biologics are large …

Alzheimer's disease is a neurodegenerative disorder that causes age-dependent
neurological and cognitive declines. The treatments for Alzheimer's disease pose a …

Alzheimer's disease (AD) is the most common form of dementia. AD brain pathology starts
decades before the onset of clinical symptoms. One early pathological hallmark is blood …

The blood-brain barrier (BBB) is involved in the pathogenesis of Alzheimer's disease (AD).
BBB is a highly selective semipermeable structural and chemical barrier which ensures a …

Vascular dysfunction is frequently observed in disorders associated with cognitive
impairment, dementia and Alzheimer's disease (AD). Recent advances in neuroimaging and …

The blood-brain barrier (BBB) mediates the communication between the periphery and the
central nervous system (CNS). Recently, CNS insulin resistance has been elucidated to play …

Cerebral small vessel disease (cSVD) comprises pathological processes of the small
vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or …

Cerebral “microvascular” disease occurs in lacunar stroke, leukoaraiosis, vascular dementia
and Alzheimer's disease. It may arise from or contribute to insidious damage to the blood …